AzTrials
AzTrials

ObesityEPI-SPERMNCT03962699

Impact of Weight Loss on the Human Sperm Epitranscriptome

An observational study of Obesity, run by Institut National de la Santé Et de la Recherche Médicale, France at 1 site in France.

Active, not recruiting

Under way, not looking for participants. Everyone needed has enrolled. The study is still running.

Official record
Search all trials

Trial summary

Increasing evidence suggests that non-communicable diseases such as in particular obesity and its associated metabolic diseases are inherited from parents to children throughout several generations by epigenetic mechanisms. Read more about this study

Who is it for?
Ages 20 to 50 years, men onlyHealthy volunteers can take part
Conditions the study is for
Obesity
How many people
45 participants
Where
1 siteFrance
Study dates
20 Jul 2019to 19 Dec 2025
Phase
Observational
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 20 to 50 years
  • Men only
  • Healthy volunteers accepted
  • Adult

Study population: Inclusion Criteria: * selected for a bariatric surgery by a multidisciplinery team * aged between 20-50 years * does not show their opposition to participate in the research study * presented no difficulties in oral and written comprehension of french language. Exclusion Criteria: * men exhibiting less than 1 000 000 spermatozoa/ejaculate * men who are not compliant with the research study

Who may be able to join

  • exhibiting a normal BMI from 18 to 25
  • aged between 20-50 years
  • selected as fertile men in the context of a a medical consultation in Reproduction Biology laboratories
  • does not show their opposition to participate in the research study
  • presented no difficulties in oral and written comprehension of french language.

Who cannot join

None listed.

Trial locations and contacts

1 site in 1 country.

France1 site
  • Hopital Archet

    Nice, 06202

Other trials in France

About this study

Increasing evidence suggests that non-communicable diseases such as in particular obesity and its associated metabolic diseases are inherited from parents to children throughout several generations by epigenetic mechanisms. Thus, this environmental stress would induce epigenetic modification in the germ line that once transmitted and maintained in the progeny would induce the development of the parental pathologies. Considering the increasing prevalence of these pathologies worldwide, we urgently need to understand this process in human. Based on published and unpublished data demonstrating that sperm RNAs are vectors of epigenetic inheritance of obesity mouse model, the investigative team hypothesizes that epitranscriptome of obese men play a central role in the paternal epigenetic inheritance of obesity and its associated metabolic diseases as epigenetic vectors in this process.

To validate this hypothesis, the investigative team will use sperm from non-obese and obese men taken before and after surgery weight loss. Thanks to these cohorts, they propose to: (i) compare the epitranscriptome profiles of non-obese and obese men to identify the RNAs molecules which will be either qualitatively or quantitatively epigenetically modulated by obesity; (ii) compare the epitranscriptome profiles of obese men before and after surgery-weight loss to assess the reversibility of the newly acquired RNA modifications.

Giving some answers to this central question will provide not only some clues about the molecular mechanisms involved in this process, elements which might be crucial to stop the spread of this disorder, but will also allow the identification of obese-susceptibility loci which expression may be modulate by environmental factors and consequently able to transmit the disease.

Read the detailed description
  1. Background and present state of the art in the research field. Sperm non-coding RNA is an important vector for epigenetic inheritance of diet-induced obesity Obesity is a multifactorial pathology associated with a high heritability (50-75%). To date, multiple Genome Wide Association Studies (GWAS) have attempted and failed to identify the genetic factors that contribute to the etiopathogenesis of obesity. In fact, the variance explained by a high Body Mass Index (BMI) at these GWAS mutations is very low, estimated to be approximately 2%. Recent epidemiological and experimental studies strongly suggest that this high heritability of obesity might be associated with the transmission of obesity-induced epigenetic modifications. Non-genetic inheritance of a newly acquired phenotype is a concept in biology whereby changes induced by a specific signal and/or environmental stress can be passed to the next generation in the absence of a genetic change. The biological relevance of this process is proven by its diversification in various organisms including plants, insects, nematodes, and mammals. However, evidence is now emerging that a wide range of dietary factors including fats and proteins lead to changes in gene expression that are maintained through mitotic and meiotic divisions. These changes can significantly impact the health of the offspring. Very recently, the investigator has gained some insight into the molecular mechanisms involved in this process, in particular those that pertain to the epigenetic inheritance of newly acquired paternal pathologies. However, much remains to be uncovered about the functional and molecular characterization underlying the mode of action of the specific factors responsible. Changes in DNA methylation, chromatin modification and expression levels of non-coding small RNA, including miRNA, piRNA and transfer RNA fragments occur in germ cells upon changes in environmental cues. However, it is not clear whether these changes would mediate epigenetic inheritance. While several studies have indicated that an altered DNA methylation signature of spermatozoa from HFD-obese individuals could be transmitted to progeny, a recent study indicated that the sperm methylome is shaped by genetic and epigenetic variations, but not diet, thus disproving the idea that DNA methylation is the vector of epigenetic inheritance in this HFD model. Based on this first evidence showing that small non-coding RNAs (sncRNAs) act as trans-generational vectors of epigenetic information in mice, the investigative team and others extended this discovery by deep investigation of the role of sperm small RNAs as determinants of the inheritance in an acquired metabolic disorder. In this regard, experimental approaches include the micro-injection of one-cell embryos with well-defined sperm RNAs from individuals fed by high-fat (HFD) or control diet (CD). They found that mice derived from the microinjection of HFD sperm RNAs into naive one-cell embryos developed adult onset diet-induced pathologies, such as obesity or signs of type 2 diabetes even though they had been fed a control diet. Deep-sequencing analysis of small RNAs of testis from HFD-fed animals and control revealed that several small-RNAs are indeed deregulated upon HFD. Among those small RNAs, we found miRNAs, piRNAs and tRNA-derived small RNAs (tsRNA). Importantly, microinjection into naive one-cell embryos of one of the deregulated microRNAs - namely microRNA-19b, induced metabolic alterations that were similar to the diet-induced phenotypes. Likewise, other groups found that tsRNA may also contribute to intergenerational inheritance of metabolic disorders. Indeed, Chen et al. showed that micro-injecting sperm tsRNAs from HFD-fed individuals into naive one-cell embryos caused impaired glucose tolerance in the resulting offspring. However, in this model, synthetic microRNAs or synthetic tsRNAs did not induce metabolic disorders in the offspring, suggesting a role of post-transcriptional RNA modifications in the transfer of epigenetic information. This hypothesis is consistent with the elevated levels of m5C and m2G modifications of tsRNAs in sperm from the HFD group. Hence, sperm small RNAs represent a type of paternal epigenetic vector involved in intergenerational inheritance of diet-induced metabolic phenotypes. The majority of data on RNA-mediated epigenetic inheritance are from mouse models. Whether this mechanism is conserved in human as yet unknown. Noteworthy, a study performed in human by Donkin et al. indicated that obesity might modify the sperm epigenetic landscape as well as sperm epitranscriptome. However, epigenetic and transcriptomic analysis were performed in only a small number of men Taken together these observations from human and rodent studies suggest that obesity-induced small RNA changes are transmitted to the next generation, and then result in heritable metabolic changes. However, although in rodents the obesity-induced changes have been quite well described, the impact of obesity on the sperm epitranscriptome/epigenome in human remains an open question of urgency in the field. Reversal of the obesity-induced epigenetic changes: a hope for the next generation? Although epigenetic modifications are mitotically heritable, they are erased and re-established twice during development. This reprogramming takes place early in embryogenesis and during gametogenesis in primordial germ cells that will give rise to eggs and sperm. Furthermore, phenotypes conferred by environmental compromise can also be reversed via active intervention, such as change to healthy diet or physic exercise during the preconception period. It is not understood whether there is a relationship between developmental reprogramming and reversibility of environmentally induced phenotypic states. Although the erasure of these newly established modifications has been clearly described in rodents only limited studies have been addressed in human. Those studies only focused on DNA methylation pattern modulated by obesity in somatic and germ cells. To date, nothing is known about the reversibility of trans-generational epigenetic RNA in human sperm. Preliminary results Obesity negatively impacts on sperm epigenome and early embryonic development in human After having demonstrated the role of sperm RNA (small and long RNA) in paternal heredity of obesity and its associated diseases, the investigative team is currently investigating the relevance of sperm RNA-mediated epigenetic inheritance of metabolic disorders in human. To achieve this goal, they have carried out two complementary sets of experiments. First, they recently found that the development capacity of human embryos derived from obese men was impaired and noted that pre-implantation embryo morphokinetic parameters were altered when sperm derived from obese fathers was used to fertilize oocytes, suggesting obesity induced epigenetic changes in sperm. Then, to determine whether obesity induced sperm small-non coding RNA dysregulation in human, they performed a small RNA-seq differential expression analysis between obese and non-obese subjects. Briefly, upon multivariant analysis (Principal Component Analysis, PCA), they identified distinct small RNA profiles between obese and lean men. However, while sperm small RNA profiles among lean men (N1, N2, N3 and N4 samples) were homogeneous, small RNA profiles among obese men (O1, O2, O3 and O4 samples) were very heterogeneous, suggesting stochastic dysregulation of sperm small RNA expression in obesity. Together, our results highlight the negative impacts of excessive weight mass on the sperm epi-transcriptome and human early embryo development and strongly suggest that paternal obesity negatively affects the sperm epigenome and subsequently influences the health of the descendants.
  2. Descriptive of the objectives Based on the published and unpublished data described above, the investigative team hypothesize that epi-transcriptomes are responsive to transient environmental changes such as obesity, leading to modulation of the progeny's epigenomes in human and subsequently to the development of the father's phenotypes.

To validate this hypothesis, the investigator will use sperm collected from 2 groups of men: the first group will be composed of non-obese men and the second one will be composed of obese men taken before and after weight loss induced by surgery. Thanks to these cohorts, we propose to:

  • Identify the sperm epitranscriptomic signature of obese men Team 1 has recently demonstrated that sperm RNAs are vectors of epigenetic inheritance of obesity and its associated pathologies in mice. In parallel, while confirming the role of these RNAs in epigenetic inheritance, two other independent groups have shown the involvement of RNA posttranscriptional modifications in this process in mice. However, it is important to determine whether such process exists for human. By combining the complementary expertise of three groups in either epigenetic inheritance in mice (Team1) and in the handling and collection of human sperm samples (Teams 2 and 3), the investigative team will have the opportunity to answer this unresolved question.
  • Study the reversibility of the sperm epitranscriptomic signature of obese men The question of reversibility of sperm epigenetic signature induced by obesity in human is an important question in term of public health. Barrey's group has recently shown a possible reversion of obesity-induced epigenetic upon surgically incurred-weight loss. However, this study relies on sperm DNA methylation studies. The role of DNA methylation as vector of epigenetic inheritance of obesity remains to be established, however, we and others have recently demonstrated the involvement of sperm epitranscriptome in this process in mice. The possible reversibility of these obese-induced epitranscriptomic changes remains to be demonstrated both in mice and in human.

The impact of bariatric surgery with weight loss on metabolic health in progeny of obese fathers could be, in principle, studied directly on human cohorts. However, the few longitudinal studies currently available from offspring born after parental weight loss are based on maternal weight loss studies. These results are not only inconsistent but also biased by the fact that the surgery procedure leads to malnutrition risks in the mother. Given the importance of nutrition during pregnancy, the potential impact of surgical weight loss on gametic epigenomic reversibility and on metabolic health of offspring could not be evaluated in this context. By performing comparison of epitranscriptomic profiles between obese men before and after surgery, the investigative team will bring new insights into this very important biological question.

The investigative team expect that this proposal will provide clues about the molecular mechanisms involved in this process, and will allow the identification of obese-susceptibility loci as well, which their expression may be modulated by environmental factors and consequently affects the inheritance of the disease.

Conditions
Obesity
Keywords
sperm, Epigenetic, RNA
Medical subject headings
Obesity

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

Study groups in NCT03962699
Study groupRoleWhat they receive
Obese patients selected for bariatric surgeryNormospermic obese patients ((BMI>40), aged 20-50 years) who will undergo Bariatric surgery.
Control Group: Non obese volunteersNormospermic obese patients ((BMI>40), aged 20-50 years

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Impact of weight loss on sperm transcriptome of obese men

    To evaluate the impact of weight loss on sperm transcriptome, sperm RNA from obese men will be analyzed by RNA-seq before and one year after bariatric surgery. The supplied samples will be sequenced on the Illumina NextSeq500 and the resulting RNA-Seq Data will be bioinformatically analyzed.

    Measured: Between day 0 and day 365: collection of sperm samples from obese men before bariatric surgery. Between day 370 and 735: collection of the sperm sample from obese men after bariatric surgery. Day 740-800; RNA-seq and data analysis

Secondary outcomes (1)
  1. Impact of obesity on sperm transcriptome of obese men

    Sperm RNA from obese and non-obese men will be analyzed by RNA-seq. The supplied samples will be sequenced on the Illumina NextSeq500 and the resulting RNA-Seq Data will be bioinformatically analyzed.

    Measured: Day 0 to Day 365: collection of sperm samples from obese and non-obese men. Day 740-800; RNA-seq and data analysis

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted24 May 2019
  2. Study start20 Jul 2019
  3. Primary completion19 Dec 2025 (estimated)
  4. Study completion19 Dec 2025 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Case-control
Time perspective
Retrospective
Enrolment
45 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT03962699
Sponsor's protocol ID
C18-55
Other IDs
2019-A00833-54
Acronym
EPI-SPERM
Status last verified
Mar 2025
First submitted
22 May 2019
Last updated
26 Mar 2025
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Questions about this trial

What is this clinical trial studying?

An observational study of Obesity, run by Institut National de la Santé Et de la Recherche Médicale, France at 1 site in France.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 5 inclusion and 0 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: under way, not looking for participants, as of the sponsor's last update on 26 Mar 2025. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in France. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Impact of weight loss on sperm transcriptome of obese men (time frame: Between day 0 and day 365: collection of sperm samples from obese men before bariatric surgery. Between day 370 and 735: collection of the sperm sample from obese men after bariatric surgery. Day 740-800; RNA-seq and data analysis). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 26 Mar 2025.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in